Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness
This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce facial redness typically associated with rosacea. Approximately 25 subjects will be enrolled. Subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (BL, W1, W2, W4).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
25
BID application
Cage Bio Investigative Site 1
Fremont, California, United States
Cage Bio Investigative Site 2
San Diego, California, United States
Cage Bio Investigative Site 3
Edgewater, Florida, United States
Investigator's Global Assessment of Redness (IGA-R)
5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness)
Time frame: 4 weeks
Investigator's Global Assessment of Redness (IGA-R)
5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness)
Time frame: Day 0, Week 1, Week 2
Patient Global Assessment
5-point scale (0: excellent effectiveness; 1: good effectiveness; 2: Effective; 3: No significant benefit and 4: No benefit at all)
Time frame: Week 1, Week 2, Week 4
Bumps/Blemishes Count
Numerical count of Bumps/Blemishes
Time frame: Day 0, Week 1, Week 2, Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.